in hospitalized patients and can disseminate to cause candidemia in susceptible host. It has been shown in animal model that gut of antibiotic-treated mice can act as a reservoir for C. glabrata. It would be enlightening if the authors can report the data regarding, nature of surgeries done in the surgical group.
Hospitalized patients are frequently colonized with Candida. Risk of candidemia increases with increase in density of colonization and number of colonized sites. [5] The method used for identifying urine as the most common source of C. glabrata candidemia needs to be mentioned in the study. Authors have stated that candiduria is a useful indicator for systemic candidiasis, but it is unclear from the results that what were the other sites looked for. Interpreting the source of candidemia without studying different sites for colonization and typing the strain can give misleading results.
Local epidemiology is important to guide empirical antifungal therapy. More studies are needed to identify the risk factors for C. glabrata infection and colonization as well as to conduct external validation of already existing risk models.
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Antimicrobial dosing in critically ill patients with sepsis-induced acute kidney injury
Sir, We read with interest the article by Anish Kumar et al. [1] It is an extremely important issue in critical care settings considering the incidence and high mortality rates associated with sepsis and the subsequent development of acute kidney injury (AKI). The antibiotics are one of the most important armamentarium in dealing with this problem. If we do not get the right dose at right time then it not only increases mortality, but also leads to subsequent development of infection with resistant organisms. The article adds to our improved understanding of the usage of antibiotics in septic AKI patients. The article has very well elaborated the factors that can affect the dosing of the antibiotics and how to give the appropriate dosage for most of the commonly used antibiotics.
There has been a significant epidemiological shift in the resistance patterns in intensive care unit (ICU) worldwide. Multidrug-resistant Pseudomonas and Acinetobacter have been the prototypical nosocomial pathogens for the past few decades. These organisms may be eclipsed by a rapidly growing global epidemic of cephalosporin and carbapenem-resistant Enterobacteriaceae. These organisms have been detected in India since 2006. [2] They continue to be a major source of nosocomial infections especially in Indian ICUs.
The use of colistin and tigecycline to deal with the changed epidemiology has increased in ICUs. [3] These drugs have their own unique pharmacokinetic and pharmacodynamic profile. This review does not highlight about the factors that may affect the pharmacokinetic s and dynamics of these drugs in AKI. The dosing regimen of colistin may also vary with different modalities of renal replacement therapy, and needs to be discussed as recommended by different authors. [4, 5] The renal toxicity of colistin is said to be overestimated in past studies. We need new studies to look for dosing of colistin especially in septic AKI patients and reviews must address this issue.
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CytoSorb-friend or foe!!
Sir, We read the case report "use of a novel hemadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: A case study" by Basu et al. [1] with great interest.
We would like to share our experiences with a similar patient in our Intensive Care Unit and discuss some of the intriguing points.
We had a 79-year-old male patient in severe septic shock (urosepsis) with multi-organ failure (acute o n c h r o n i c r e n a l f a i l u r e , a c u t e r e s p i r a t o r y distress syndrome, Arterial hypotension, drowsy mentation), acute physiology and chronic health evaluation (APACHE II) score on admission was 32, started on CytoSorb (CytoSorbents Corporation, USA) therapy along with sustained low effusion dialysis (SLED) in citrate at a flow rate of 100 ml/min, with in 15 h of admission along with standard surviving sepsis guidelines treatment.
He improved with 3 days of CytoSorbe hemadsorption along with SLED for 6 h every day, as reflected by improved hemodynamic parameters, ventilator requirements along with increasing urine output. He had improved to APACHE II score of 8 after day 3 of therapy, and his interleukin-6 (IL-6) levels, which were to start with 1356.3 pg/ml dropped down to 26.12 pg/ml. However, he started to deteriorate clinically on 5 th day onwards despite all on-going supportive care, let us think about the immune-modulation done with CytoSorb therapy.
CytoSorb contains adsorbent polymer beards that adsorb cytokines as blood pass through the device. Among cytokines, there are few harmful pro-inflammatory cytokines like IL-1, 6, 8 and tumor necrosis factor and few useful anti-inflammatory cytokines like IL-10 and tumor growth factor-β. [2] Does the CytoSorb hemadsorption distinguishes among them needs to be ascertained? As our case probably deteriorated due to immunosuppression by the removal of helpful anti-inflammatory cytokines.
So perhaps randomized controlled trials are necessary to check the risk-benefit ratio of hemadsorption therapy in severe septic patients.
